RVMD – Revolution Medicines, Inc.
Revolution Medicines, Inc.RVMD
$46.57Name : Revolution Medicines, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $8,705,478,656.00
EPSttm : -4.52
Revolution Medicines, Inc.
$46.57
0.02%$0.01Float Short %
11.14
Margin Of Safety %
Put/Call OI Ratio
0.4
EPS Next Q Diff
-0.2
EPS Last/This Y
-1.71
EPS This/Next Y
-0.64
Price
46.57
Target Price
75.47
Analyst Recom
1.06
Performance Q
20.9
Relative Volume
0.46
Beta
1.23
Ticker: RVMD
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | RVMD | 41.04 | 0.35 | 5.17 | 43862 |
| 2025-09-09 | RVMD | 40.94 | 0.36 | 2.73 | 44076 |
| 2025-09-10 | RVMD | 40.45 | 0.35 | 2.55 | 44199 |
| 2025-09-11 | RVMD | 46.3 | 0.36 | 0.95 | 44150 |
| 2025-09-12 | RVMD | 46.53 | 0.38 | 0.25 | 45397 |
| 2025-09-15 | RVMD | 46.21 | 0.38 | 0.59 | 45582 |
| 2025-09-16 | RVMD | 44.7 | 0.38 | 0.23 | 45804 |
| 2025-09-17 | RVMD | 43.81 | 0.38826538287949 | 0.014961725817676 | 46139 |
| 2025-09-18 | RVMD | 45.23 | 0.42 | 0.11 | 43591 |
| 2025-09-22 | RVMD | 44.4 | 0.39 | 4.01 | 40357 |
| 2025-09-23 | RVMD | 44.22 | 0.41 | 1.41 | 40985 |
| 2025-09-24 | RVMD | 43.54 | 0.41 | 1.40 | 41032 |
| 2025-09-25 | RVMD | 42.52 | 0.41 | 1.37 | 41092 |
| 2025-09-26 | RVMD | 43.91 | 0.41 | 4.57 | 41138 |
| 2025-09-29 | RVMD | 46.08 | 0.41 | 0.09 | 41187 |
| 2025-09-30 | RVMD | 46.7 | 0.41 | 0.98 | 41590 |
| 2025-10-01 | RVMD | 45.87 | 0.41 | 1.75 | 41685 |
| 2025-10-02 | RVMD | 45.64 | 0.41 | 7.96 | 41706 |
| 2025-10-03 | RVMD | 46.72 | 0.40 | 0.98 | 41514 |
| 2025-10-06 | RVMD | 46.58 | 0.41 | 1.31 | 42136 |
| 2025-10-07 | RVMD | 46.56 | 0.40 | 0.39 | 42120 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | RVMD | 41.06 | -49.8 | -429.7 | -5.30 |
| 2025-09-09 | RVMD | 40.94 | -49.8 | -399.9 | -5.30 |
| 2025-09-10 | RVMD | 40.46 | -49.8 | -384.4 | -5.30 |
| 2025-09-11 | RVMD | 46.24 | -49.8 | -659.0 | -5.30 |
| 2025-09-12 | RVMD | 46.56 | -49.8 | -417.3 | -5.30 |
| 2025-09-15 | RVMD | 46.21 | -47.7 | -392.6 | -5.24 |
| 2025-09-16 | RVMD | 44.70 | -47.2 | -350.2 | -5.24 |
| 2025-09-17 | RVMD | 43.76 | -47.2 | -369.3 | -5.24 |
| 2025-09-18 | RVMD | 45.22 | -47.2 | -460.9 | -5.24 |
| 2025-09-19 | RVMD | 43.58 | -47.2 | -342.9 | -5.24 |
| 2025-09-22 | RVMD | 44.41 | -47.2 | -439.9 | -5.24 |
| 2025-09-23 | RVMD | 44.17 | -47.2 | -395.9 | -5.24 |
| 2025-09-24 | RVMD | 43.54 | -47.2 | -379.4 | -5.24 |
| 2025-09-25 | RVMD | 42.51 | -47.2 | -364.4 | -5.24 |
| 2025-09-26 | RVMD | 43.92 | -47.2 | -463.0 | -5.24 |
| 2025-09-29 | RVMD | 46.05 | -49.6 | -488.9 | -5.29 |
| 2025-09-30 | RVMD | 46.67 | -49.6 | -427.5 | -5.29 |
| 2025-10-01 | RVMD | 45.87 | -49.6 | -375.1 | -5.29 |
| 2025-10-02 | RVMD | 45.65 | -49.6 | -397.4 | -5.29 |
| 2025-10-03 | RVMD | 46.69 | -49.6 | -442.0 | -5.29 |
| 2025-10-06 | RVMD | 46.54 | -49.6 | -436.5 | -5.29 |
| 2025-10-07 | RVMD | 46.57 | -49.6 | -404.9 | -5.29 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | RVMD | -0.25 | -1.43 | 9.37 |
| 2025-09-09 | RVMD | -0.25 | -1.43 | 9.37 |
| 2025-09-10 | RVMD | -0.25 | -1.43 | 9.37 |
| 2025-09-11 | RVMD | -0.25 | -1.43 | 10.20 |
| 2025-09-12 | RVMD | -0.25 | -1.43 | 10.20 |
| 2025-09-15 | RVMD | -0.25 | -1.44 | 10.20 |
| 2025-09-16 | RVMD | -0.75 | -1.44 | 10.20 |
| 2025-09-17 | RVMD | -0.75 | -1.44 | 10.20 |
| 2025-09-18 | RVMD | -0.87 | -1.44 | 10.20 |
| 2025-09-19 | RVMD | -0.87 | -1.44 | 10.20 |
| 2025-09-22 | RVMD | -0.78 | -1.45 | 10.20 |
| 2025-09-23 | RVMD | -0.78 | -1.45 | 10.20 |
| 2025-09-24 | RVMD | -0.78 | -1.45 | 10.20 |
| 2025-09-25 | RVMD | -0.77 | -1.45 | 11.14 |
| 2025-09-26 | RVMD | -0.78 | -1.45 | 11.14 |
| 2025-09-29 | RVMD | -0.78 | -1.45 | 11.14 |
| 2025-09-30 | RVMD | -0.78 | -1.45 | 11.14 |
| 2025-10-01 | RVMD | -0.78 | -1.45 | 11.14 |
| 2025-10-02 | RVMD | -0.78 | -1.45 | 11.14 |
| 2025-10-03 | RVMD | -0.78 | -1.45 | 11.14 |
| 2025-10-06 | RVMD | -0.78 | -2.47 | 11.14 |
| 2025-10-07 | RVMD | -0.78 | -2.47 | 11.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.31
Avg. EPS Est. Current Quarter
-1.41
Avg. EPS Est. Next Quarter
-1.51
Insider Transactions
-0.78
Institutional Transactions
-2.47
Beta
1.23
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
7
Growth Score
22
Sentiment Score
88
Actual DrawDown %
25.4
Max Drawdown 5-Year %
-73.3
Target Price
75.47
P/E
Forward P/E
PEG
P/S
P/B
4.67
P/Free Cash Flow
EPS
-4.5
Average EPS Est. Cur. Y
-5.29
EPS Next Y. (Est.)
-5.93
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.46
Return on Equity vs Sector %
-68.7
Return on Equity vs Industry %
-55
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.02
EBIT Estimation
-404.9
Revolution Medicines, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 700
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today
news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance
stock history RVMD – Revolution Medicines, Inc. invest stock market
stock prices RVMD premarket after hours
ticker RVMD fair value insiders trading